Hulk, really nice post below and is exactly what is always

New Post Public Reply Private Reply Replies (0) Message Board
HCIT Hulk767 #96189
622
Hulk, really nice post below and is exactly what is always in my mind lately about how hard the nerd revenge group of investors, shorts and all you mentioned that are after what we have in Leronlimab as it's the only drug that has practically no side effects and goes after the disease rather than what the big pharma companies do,they just try to stop the symptoms of diseases and their drugs have mostly horrible side effects that doctors have to prescribe other drugs to stop the bad effects of the original drugs they produce which in the end, they get to keep making the money machine pile up more and more money for them, it's a machine against man kind!

I too have not even sold 1 share since 2016 and I too won't but I will sell my cost of the original investment after our 1st of many approvals and hang on for the rest of the indications.

GLTU Hulk and thanks for posting that for it hurts what these groups of people are doing to our share price. I surely thought that $1.39 would hold from March of last year but it just blew that away at $1.36, UGH I need that pink stuff, Pepto-bismol, to calm my stomach down but I'll take what ever they throw at us and still won't sell as that's what they want us to do -

HCIT/ahab333
______________________________________________________
Hulk's post:
"i've been in for 6 years. read every article, watched every interview and listened to every call. my background is in finance (although this is my first foray into OTC land, which is a swamp - no offense to swamps).

everything in my gut tells me:

1. the science is absolutely rock-solid - and it will achieve approval in at least one massive market - which will propel the value to a large multiple of current value. the 13d group knows this - which is why they are pursuing this.

2. NP and Kelly (although they have flaws, like all of us) are working very hard, making progress, and are aligned with shareholders at this point. my view is that NP is on an absolute mission to see this through. i'll take grit over polish every time, as you can't always have both.

3. the team has learned from their mistakes - and those lessons have put us on target for some type of approval this year. i remind myself that this is how progress is ultimately made in any endeavor.

4. Picking up Recknor was a coup - he is a stud - and will carry the BLA across the goal line. I love his no-nonsense, "man of few words" approach.

i haven't sold any shares (which my wife likes to often remind me of, as she remembers it hitting $9). i have always said that i won't sell any shares until we get an approval, uplist, and are on the radar of Wall Street, BP, etc. I still expect all of that to happen - and it should coincide with a SP of greater than $10 (hopefully much greater)."
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
https://media.gettyimages.com/photos/the-grea...wdoE_swYM=
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 29

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 33

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 49

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 36

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 39

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 20

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 26

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading

Top 5 Most Recently Viewed Articles

U.S. Business Activity Hits New Heights Amid Optimism

Updated Category News Views 102

US Business Activity Surges to New Heights A significant measure of business activity in the U.S. has surged to its highest level in 31 months, driven by optimism surrounding potential lower interest rates and expected pro-business changes from the incoming administration. Composite PMI Index Shows Strong Growth S&P Global reported that its flash U.S. Composite PMI Output...

Continue Reading
Yiren Digital to Showcase Innovations at Upcoming Investor Conference

Updated Category News Views 70

Yiren Digital's Upcoming Presentation at Investor Conference Yiren Digital, a pioneering AI-driven platform that offers a wide array of financial and lifestyle services in China, is preparing for an important virtual event. On September 25, Yuning Feng, the CFO of Yiren Digital, will present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference. This event is an...

Continue Reading
HiLabs Earns Prestigious Recognition for AI Innovations

Updated Category News Views 270

HiLabs Honored by KLAS for Innovations in Healthcare HiLabs, a prominent name in AI-driven healthcare data management, has recently been recognized in the 2025 KLAS Collaborative Points of Light awards. This prestigious acknowledgment showcases HiLabs' commitment to solving significant challenges within the healthcare sector through innovative technology. The company's...

Continue Reading
Booz Allen Hamilton's CFO Makes Strategic Stock Sale Decision

Updated Category News Views 44

Booz Allen Hamilton Holding Corp. (NYSE: BAH) just served up some intriguing corporate moves with its Executive Vice President and Chief Financial Officer, Matthew Calderone, making headlines. He recently sold off 3,865 shares of the company's Class A Common Stock for a substantial total of $618,400. That kind of action doesn’t happen in a vacuum; it's a signal that...

Continue Reading
IBM's 2026 X-Force Threat Index: Cyber Risks Increasing Fast

Updated Category News Views 262

The Dark Side of AI in Cybersecurity In today's digital battleground, the stakes just got higher. IBM has dropped the 2026 X-Force Threat Intelligence Index, and it ain't pretty. We're talking about a seismic 44% spike in cyberattacks leveraging public-facing applications, all thanks to AI that gives attackers a turbo boost to find chinks in the armor. Ransomware Groups...

Continue Reading